Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures / 소아과
Korean Journal of Pediatrics
;
: 50-54, 2017.
Artigo
em Inglês
| WPRIM
| ID: wpr-168713
ABSTRACT
PURPOSE:
The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM.METHODS:
A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by a mean maintenance dose of 29 mg/kg/day.RESULTS:
Seventeen neonates (94%) had seizure cessation within 1 week and 16 (84%) remained seizure-free at 30 days under the LEV therapy. The mean serum concentration of LEV was 8.7 µg/mL. Eight samples (5%) were found above the therapeutic range. No serious adverse effects were detected. In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.CONCLUSION:
LEV is a safe and effective option for the treatment of neonatal seizures with careful therapeutic drug monitoring.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Convulsões
/
Farmacocinética
/
Estudos Retrospectivos
/
Monitoramento de Medicamentos
/
Meia-Vida
Tipo de estudo:
Estudo observacional
Limite:
Adulto
/
Humanos
/
Recém-Nascido
Idioma:
Inglês
Revista:
Korean Journal of Pediatrics
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS